Population Pharmacokinetics of Volasertib Administered in Patients with Acute Myeloid Leukaemia as a Single Agent or in Combination with Cytarabine.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Volasertib, a potent and selective polo-like kinase inhibitor, has shown to increase response rates and improve survival with a clinically manageable safety profile, administered alone and in combination with cytarabine in patients with acute myeloid leukaemia.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Clin Pharmacokinet

Title: Clinical pharmacokinetics

Publisher: Springer Science and Business Media LLC

ISSN (Electronic): 1179-1926

ISSN (Print): 0312-5963

Publication date (Electronic): March 2018

Volume: 57

Issue: 3

Affiliations

[1 ] Pharmacometrics and Systems Pharmacology, Department of Pharmacy and Pharmaceutical Technology, School of Pharmacy and Nutrition, University of Navarra, Irunlarrea 1, 31008, Pamplona, Spain.

[2 ] Navarra Institute for Health Research (IdisNA), University of Navarra, Pamplona, Spain.

[3 ] Translational Medicine and Clinical Pharmacology, Boehringer Ingelheim GmbH & Co. KG, Biberach an der Riss, Germany.

[4 ] Pharmacometrics and Systems Pharmacology, Department of Pharmacy and Pharmaceutical Technology, School of Pharmacy and Nutrition, University of Navarra, Irunlarrea 1, 31008, Pamplona, Spain. itroconiz@unav.es.

[5 ] Navarra Institute for Health Research (IdisNA), University of Navarra, Pamplona, Spain. itroconiz@unav.es.

Article

Publisher Item ID: 10.1007/s40262-017-0566-9

DOI: 10.1007/s40262-017-0566-9

PubMed ID: 28631179

SO-VID: 204fb2ac-dfdf-4ab5-84da-fe79197a9fad

History

Data availability:

Comments

Comment on this article

scite_

Cited by 5

See all cited by